A Study of Etoricoxib in Participants With Osteoarthritis Not Responding to Analgesic Drugs (MK-0663-142)

Phase 4

Withdrawn

• Conditions: Osteoarthritis
• Interventions: Drug: Etoricoxib; Drug: Placebo for etoricoxib

• Registration Number: NCT01429168
• Lead Sponsor: Organon and Co

Brief Summary

This two-part study will evaluate the effectiveness of etoricoxib in controlling pain in participants with osteoarthritis who are experiencing inadequate response to their current treatments. In Part 1, all participants will receive open-label etoricoxib 60 mg daily. Those participants who experience a clinically meaningful response to etoricoxib 60 mg daily within two weeks will be eligible to enter the double-blind withdrawal period (Part II). Responders entering Part 2 will be randomized in a 1:1 ratio to receive either etoricoxib 60 mg or placebo.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2011-09-02
• Study First Submitted QC: 2011-09-02
• Study First Posted: 2011-09-05
• Study Start: 2011-10
• Primary Completion: 2012-08
• Study Completion: 2012-08
• Status Verified: 2022-02
• Last Update Submitted: 2022-02-07
• Last Update Posted: 2022-02-18

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• Clinical diagnosis of osteoarthritis of the knee or hip that requires treatment
• American Rheumatism Association (ARA) functional Class I, II or III
• Receiving a stable dose of a traditional non-steroidal anti-inflammatory drug (NSAID), a Cox-2 selective inhibitor (other than etoricoxib, e.g. celecoxib), opioid therapy or tramadol to treat their osteoarthritis-related pain for at least 2 weeks and willing to maintain treatment during baseline phase
• Moderate to severe daily pain intensity on his or her current pain regimen
• Excepting osteoarthritis, patient is judged to be in otherwise general good health based on medical history, physical examination, and routine laboratory tests
• Negative serum pregnancy test

Exclusion Criteria

• Has not experienced at least 3 consecutive days of daily pain intensity >4 on 10-point scale
• Severe hepatic insufficiency
• Advanced renal insufficiency
• Presence of gastro-intestinal ulcer disease with active bleeding or history of the same within the past 6 months or a presence or history of inflammatory bowel disease
• History of gastric, biliary (including gastric bypass surgery), or small intestinal surgery that results in clinical malabsorption
• Receiving or will likely require treatment with ≥14 consecutive days or repeated courses of pharmacologic doses of corticosteroids
• Established ischemic heart disease, peripheral arterial disease, and/or cerebrovascular disease including a history of stroke, myocardial infarction or transient ischemic attack, and recent revascularization procedures
• Any other contraindications mentioned in the approved study drug European Union (EU) Summary of Product Characteristics (SmPC)
• Therapy with glucosamine and/or chondroitin sulfate for <6 months prior to study start.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Part 1: All Enrolled Participants	Etoricoxib	All participants will receive open-label etoricoxib 60 mg orally daily during Part 1.
Part 2: Etoricoxib	Etoricoxib	-
Part 2: Placebo	Placebo for etoricoxib	-

Primary Outcome Measures

Name	Time	Method
Mean Time to Loss of Efficacy in the Double Blind Withdrawal Period (Part 2)	Week 3 to Week 7

Secondary Outcome Measures

Name	Time	Method
Proportion of Participants who Achieve ≥30% Reduction in Pain During Part I	Week 1 to Week 3
Proportion of Participants Meeting Criteria for Loss of Efficacy in Part 2	Week 3 to Week 7
Change in Mean of Daily Pain Scores	Week 1 to Week 7